The agency took another step toward clearing a backlog of Makary-era rejections that appeared to contradict earlier agreements with drugmakers.
An article from
The agency took another step toward clearing a backlog of Makary-era rejections that appeared to contradict earlier agreements with drugmakers.
Published June 22, 2026
A sign for the Food and Drug Administration is seen on July 20, 2020, at the White Oak campus in Silver Spring, Maryland.
Sarah Silbiger via Getty Images
Regenxbio to resubmit Hunter syndrome gene therapy as FDA rare disease about-face continues
FDA reverses course on Regenxbio’s childhood gene therapy after rejection
Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy - Regenxbio (NASDAQ:RGNX)
REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
Following dispute with FDA, UniQure is cleared to submit Huntington’s treatment for approval
UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency
FDA appears open to Moderna's flu vaccine ahead of adcomm
Regenxbio plans to resubmit its Hunter syndrome gene therapy RGX-121 after the FDA reversed course, saying existing data are…
The FDA will reconsider approving Regenxbio's experimental gene therapy for a deadly and rare childhood brain disorder it…
FDA reverses its rejection of Regenxbio Navsunli, allowing the company to refile its gene therapy application.
Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a…
Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and…
The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
